Cerevel Therapeutics Signs 60K Lease at Cambridge Crossing

CAMBRIDGE, MA—Cerevel Therapeutics has signed a 59,865-square-foot lease with DivcoWest at its Cambridge Crossing complex. The deal brings the third commercial building at the complex—222 Jacobs St.—to fully leased.

The biopharmaceutical company will join Philips North America at 222 Jacobs St. in 2020. Philips North American announced it had signed a 243,000-square-foot lease at Cambridge Crossing in January 2018 and would relocate its North American headquarters to the complex that lies at the intersection of Cambridge, Somerville and Boston.

With the addition of Cerevel Therapeutics, approximately 1.3 million square-feet of commercial space is now fully leased at Cambridge Crossing, and a fourth building is now under construction, a 504,000-square-foot science and technology building at 250 Water St.

Once complete, the community will provide what developer DivcoWest describes as “a one-of-a-kind place for employees, residents, and neighbors connected to two MBTA stops and surrounded by an eclectic food scene, neighborhood retail, and more than 3,000 residences in a range of apartment and condominium buildings.”

Cerevel Therapeutics was represented by Don Domeretsky and Ben Heller, both managing directors of JLL.

Cambridge Crossing is a 43-acre, 4.5 million-square-foot transit-oriented neighborhood located at the intersection of Cambridge, Somerville, and Boston. Once complete, CX will offer 2.1 million-square-feet of state-of-the-art science and technology space, 2.4 million-square-feet of residential space that includes approximately 2,400 new units in addition to the 2,500 existing units in the neighborhood and 100,000 square-feet of retail space.